BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, September 28, 2023
Home » Blogs » BioWorld MedTech Perspectives » The difference between good news and bad news

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

The difference between good news and bad news

June 7, 2013
By Mark McCarty
No Comments

Different faces and stories, same questions?
Different faces and stories, same questions?

There’s an old story about a farmer who lost a horse, and the neighbor said “such bad news.” Then the horse came back with a bunch more in tow, and the neighbor said “such good news!” Then the farmer’s son broke his arm breaking one of the new horses and … well you get the idea. Sometimes you can tell the difference, sometimes not.

With that in mind, we examine two stories appearing recently in the pages of Medical Device Daily.

CMS; Trustees report is happy, happy

The Centers for Medicare & Medicaid Services announced recently the Medicare hospital (Part A) trust fund picked up two additional years of solvency, and CMS said “Medicare spending per beneficiary has grown quite slowly over the past few years and is projected to continue growing slowly over the next several years.”

Continue growing slowly over the next several years? Maybe. Or maybe the recession really did impose drag on Medicare spending and the economic recovery will push growth back to 6% per annum.

Mark Pauly of the Wharton School appeared at a recent confab on the Trustees report, and he remarked that hospitals and makers of therapeutics and diagnostics often shelve big plans when Medicare spending slows. Once spending growth resumes, however, all bets are off.

CMS also claimed the Affordable Care Act helped put a lid on Medicare inflation, but Pauly pointed out that many such fixes exert an ephemeral effect, as was the case with managed care.

I’m not trying to unload on CMS here – it is their job to make the government’s case after all – but I doubt anyone who’s familiar with the territory broke out the bubbly in response to the report, which one could say was bad news for makers of champagne.

Warning letter to Edwards; very big ouch

Edwards Lifesciences announced recently it had received a warning letter from FDA, but it was one of the longest warning letters I’ve ever seen, and I’ve seen a bunch.

Edwards announced a recall during the course of the inspection, but one of the big issues was the firm’s validation of an oven used in the processing of the QuickDraw venous cannulae, which seems to have led to breakage of the cannulae on six occasions.

Are six broken cannulae conspicuous? I can’t say because I have no idea how many were manufactured during the period in question, but worse yet in FDA’s view was that the company changed its story about the cause of the broken cannulae.

I’m not arguing criminal negligence, just that this is interventional cardiology, not a region that’s particularly forgiving of problems, which is why FDA is not particularly forgiving of problems, either.

I’d also point out the agency recently raised the question of Park doctrine in a warning letter to a food producer, and makers of these very high-risk devices would do well to read the tea leaves. Is it a stretch to think government prosecutors would invoke Park doctrine over the results of an inspection of a device maker?

Not if someone died.

The good news here is the Edwards compliance team will visit the plant in Draper, Utah, and tighten some bolts. The bad news is device makers must push the boundaries of design and materials science to reliably manufacture these smaller, more complex devices, and it doesn’t take a big mistake for problems to arise.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 27, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 27, 2023.
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • Apple Computer Inc. logo

    Apple scores win over Masimo for patents for physiological detectors, but ITC decision awaits

    BioWorld MedTech
    Apple Inc., of Cupertino, Calif., has prevailed over Masimo Corp., in a ruling at the U.S. Court of Appeals for the Federal Circuit, an outcome that invalidated...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing